ES2610652T3 - Ésteres de ácidos amidoxima-carboxílicos de la pentamidina como profármacos y su utilización como un medicamento - Google Patents
Ésteres de ácidos amidoxima-carboxílicos de la pentamidina como profármacos y su utilización como un medicamento Download PDFInfo
- Publication number
- ES2610652T3 ES2610652T3 ES11175252.3T ES11175252T ES2610652T3 ES 2610652 T3 ES2610652 T3 ES 2610652T3 ES 11175252 T ES11175252 T ES 11175252T ES 2610652 T3 ES2610652 T3 ES 2610652T3
- Authority
- ES
- Spain
- Prior art keywords
- pentamidine
- prodrugs
- esters
- medicine
- carboxylic acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 pentamidine amidoxime carboxylic acids Chemical class 0.000 title description 7
- 239000000651 prodrug Substances 0.000 title description 7
- 229940002612 prodrug Drugs 0.000 title description 7
- 239000003814 drug Substances 0.000 title 1
- 150000002148 esters Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 19
- 229960004448 pentamidine Drugs 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011534 incubation Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229940079919 digestives enzyme preparation Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- UVADNHMLTJNGDH-UHFFFAOYSA-N n'-hydroxy-4-[5-[4-(n'-hydroxycarbamimidoyl)phenoxy]pentoxy]benzenecarboximidamide Chemical compound C1=CC(C(=N\O)/N)=CC=C1OCCCCCOC1=CC=C(C(\N)=N/O)C=C1 UVADNHMLTJNGDH-UHFFFAOYSA-N 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- OXPMCNJABSKCMN-DQEYMECFSA-N [(z)-[amino-[4-[5-[4-[(z)-n'-[(2s)-2-amino-3-methylbutanoyl]oxycarbamimidoyl]phenoxy]pentoxy]phenyl]methylidene]amino] (2s)-2-amino-3-methylbutanoate Chemical compound C1=CC(C(/N)=N/OC(=O)[C@@H](N)C(C)C)=CC=C1OCCCCCOC1=CC=C(C(\N)=N\OC(=O)[C@@H](N)C(C)C)C=C1 OXPMCNJABSKCMN-DQEYMECFSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
- C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11175252.3A EP2550963B1 (de) | 2011-07-25 | 2011-07-25 | Pentamidin-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2610652T3 true ES2610652T3 (es) | 2017-04-28 |
Family
ID=46514404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11175252.3T Active ES2610652T3 (es) | 2011-07-25 | 2011-07-25 | Ésteres de ácidos amidoxima-carboxílicos de la pentamidina como profármacos y su utilización como un medicamento |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20130085180A1 (enExample) |
| EP (1) | EP2550963B1 (enExample) |
| JP (2) | JP2014529579A (enExample) |
| KR (1) | KR20140097108A (enExample) |
| CN (1) | CN103874491A (enExample) |
| AU (1) | AU2012288968B2 (enExample) |
| BR (1) | BR112014001787A2 (enExample) |
| CA (1) | CA2842355A1 (enExample) |
| DK (1) | DK2550963T3 (enExample) |
| ES (1) | ES2610652T3 (enExample) |
| HR (1) | HRP20170013T1 (enExample) |
| HU (1) | HUE030245T2 (enExample) |
| LT (1) | LT2550963T (enExample) |
| PL (1) | PL2550963T3 (enExample) |
| PT (1) | PT2550963T (enExample) |
| RS (1) | RS55557B1 (enExample) |
| RU (1) | RU2608388C2 (enExample) |
| SI (1) | SI2550963T1 (enExample) |
| WO (1) | WO2013014059A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9375411B2 (en) | 2012-12-21 | 2016-06-28 | Verlyx Pharma Inc. | Uses and methods for the treatment of liver diseases or conditions |
| WO2019067696A1 (en) * | 2017-09-27 | 2019-04-04 | Ohio State Innovation Foundation | METHODS AND COMPOSITIONS FOR INHIBITING STAT3 |
| US10835581B2 (en) | 2017-11-28 | 2020-11-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Method of treating insulin resistance |
| WO2020132636A1 (en) * | 2018-12-20 | 2020-06-25 | Auransa Inc. | Analogues of pentamidine and uses therefor |
| WO2024211870A2 (en) * | 2023-04-07 | 2024-10-10 | Auransa Inc. | Pentamidine analogue polymorphs, formulations, and methods thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4321444A1 (de) * | 1993-06-28 | 1995-01-05 | Bernd Prof Dr Clement | Pharmazeutische Zubereitung |
| US5723495A (en) * | 1995-11-16 | 1998-03-03 | The University Of North Carolina At Chapel Hill | Benzamidoxime prodrugs as antipneumocystic agents |
| US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| DE102008007381A1 (de) | 2008-02-01 | 2009-08-13 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg | Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten |
-
2011
- 2011-07-25 DK DK11175252.3T patent/DK2550963T3/en active
- 2011-07-25 EP EP11175252.3A patent/EP2550963B1/de not_active Not-in-force
- 2011-07-25 PT PT111752523T patent/PT2550963T/pt unknown
- 2011-07-25 RS RS20170002A patent/RS55557B1/sr unknown
- 2011-07-25 PL PL11175252T patent/PL2550963T3/pl unknown
- 2011-07-25 LT LTEP11175252.3T patent/LT2550963T/lt unknown
- 2011-07-25 HU HUE11175252A patent/HUE030245T2/en unknown
- 2011-07-25 ES ES11175252.3T patent/ES2610652T3/es active Active
- 2011-07-25 SI SI201131053A patent/SI2550963T1/sl unknown
-
2012
- 2012-07-19 BR BR112014001787A patent/BR112014001787A2/pt not_active IP Right Cessation
- 2012-07-19 WO PCT/EP2012/064171 patent/WO2013014059A1/de not_active Ceased
- 2012-07-19 AU AU2012288968A patent/AU2012288968B2/en not_active Ceased
- 2012-07-19 CN CN201280037041.7A patent/CN103874491A/zh active Pending
- 2012-07-19 JP JP2014522041A patent/JP2014529579A/ja not_active Withdrawn
- 2012-07-19 RU RU2014106867A patent/RU2608388C2/ru not_active IP Right Cessation
- 2012-07-19 CA CA2842355A patent/CA2842355A1/en not_active Abandoned
- 2012-07-19 KR KR1020147004770A patent/KR20140097108A/ko not_active Withdrawn
- 2012-10-05 US US13/554,536 patent/US20130085180A1/en not_active Abandoned
-
2016
- 2016-09-06 JP JP2016173855A patent/JP2017039727A/ja not_active Withdrawn
-
2017
- 2017-01-05 HR HRP20170013TT patent/HRP20170013T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140097108A (ko) | 2014-08-06 |
| US20130085180A1 (en) | 2013-04-04 |
| HUE030245T2 (en) | 2017-04-28 |
| JP2014529579A (ja) | 2014-11-13 |
| HRP20170013T1 (hr) | 2017-03-10 |
| RS55557B1 (sr) | 2017-05-31 |
| PT2550963T (pt) | 2017-01-19 |
| AU2012288968B2 (en) | 2017-01-05 |
| BR112014001787A2 (pt) | 2017-02-21 |
| JP2017039727A (ja) | 2017-02-23 |
| AU2012288968A1 (en) | 2014-02-13 |
| SI2550963T1 (sl) | 2017-05-31 |
| CA2842355A1 (en) | 2013-01-31 |
| RU2608388C2 (ru) | 2017-01-18 |
| DK2550963T3 (en) | 2017-01-30 |
| CN103874491A (zh) | 2014-06-18 |
| WO2013014059A1 (de) | 2013-01-31 |
| PL2550963T3 (pl) | 2017-08-31 |
| EP2550963B1 (de) | 2016-10-12 |
| EP2550963A1 (de) | 2013-01-30 |
| RU2014106867A (ru) | 2015-08-27 |
| LT2550963T (lt) | 2017-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2610652T3 (es) | Ésteres de ácidos amidoxima-carboxílicos de la pentamidina como profármacos y su utilización como un medicamento | |
| Zuhra et al. | Cystathionine-β-synthase: molecular regulation and pharmacological inhibition | |
| Yang et al. | S-persulfidation: chemistry, chemical biology, and significance in health and disease | |
| Baldini et al. | Adipocyte hypertrophy parallels alterations of mitochondrial status in a cell model for adipose tissue dysfunction in obesity | |
| Sanchez-Roman et al. | Forty percent methionine restriction lowers DNA methylation, complex I ROS generation, and oxidative damage to mtDNA and mitochondrial proteins in rat heart | |
| ES3033538T3 (en) | Novel compounds for treating mitochondrial disease | |
| US20210284626A1 (en) | Activity-based probe compounds, compositions, and methods of use | |
| Wei et al. | Itaconate protects ferroptotic neurons by alkylating GPx4 post stroke | |
| Hong et al. | Growth, digestive and absorptive capacity and antioxidant status in intestine and hepatopancreas of sub-adult grass carp Ctenopharyngodonidella fed graded levels of dietary threonine | |
| Pérez-Sala et al. | Appraising the role of astrocytes as suppliers of neuronal glutathione precursors | |
| ES2611610T3 (es) | Ésteres de ácidos amidoxima-carboxílicos de dabigatrán como profármacos y su utilización como un medicamento | |
| Kobayashi et al. | Cystine/glutamate transporter, system xc−, is involved in nitric oxide production in mouse peritoneal macrophages | |
| Jiang et al. | An endoplasmic reticulum-targeting fluorescent probe for the imaging of GSH in living cells | |
| Pinnen et al. | Codrugs linking L-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson’s disease | |
| TR200102811T2 (tr) | Oral uygulama için, tolpersiyon içeren farmasötik preparat. | |
| Yeon et al. | Mdivi-1, mitochondrial fission inhibitor, impairs developmental competence and mitochondrial function of embryos and cells in pigs | |
| Hu et al. | Oxidative damage repair by glutamine in fish enterocytes | |
| Wu et al. | Treatment with hydrogen molecule attenuates cardiac dysfunction in streptozotocin-induced diabetic mice | |
| Castelli et al. | Adaptive antioxidant response to mitochondrial fatty acid oxidation determines the proliferative outcome of cancer cells | |
| Itoh | Drug discovery researches on modulators of lysine-modifying enzymes based on strategic chemistry approaches | |
| ECSP045215A (es) | Metabolitos del ácido (3-{[4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi) acético | |
| ES2917982T3 (es) | Método para tratar trastornos hepáticos | |
| CN109776564A (zh) | 一种氧杂蒽结构的亚铁离子荧光探针及其合成方法和应用 | |
| CN103951673A (zh) | 一种试剂及其在硫醇检测中的应用 | |
| Liao et al. | Mechanisms of high-glucose-induced mitochondrial damage and glycolipid accumulation in largemouth bass |